OTC Obesity - Singapore

March 2010 | 32 pages | ID: O62F56F5F36EN
Euromonitor International Ltd

Abstracts

OTC obesity observed 1% current value growth to attain S$1 million sales in 2009. There were reports citing possible liver damage when consuming the OTC obesity drug Ecumenical during 2009 whereby consumers were advised to see a doctor if they encountered side effects such as fever, nausea or jaundice. This is thus likely to have a spillover effect on OTC obesity’s performance, which limited its overall growth.

Euromonitor International's OTC Obesity Products in Singapore report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Consumer Health industry;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

OTC Obesity in Singapore
Euromonitor International
March 2010

LIST OF CONTENTS AND TABLES

Executive Summary
Consumer Healthcare Maintains Positive Performance in 2009
Consumers Continue To Be More Health-conscious and Cautious
International Players Remain Dominant in Consumer Healthcare
Chemists/pharmacies and Parapharmacies/drugstores Continue To Be Key
Consumer Healthcare Expects Healthy Growth
Key Trends and Developments
Image-conscious Consumers Turn To Consumer Healthcare Products
Consumers Continue To Spend on Consumer Healthcare Products Amidst the Recession
Campaigns Launched by Government To Encourage Healthier Living
Consumer Healthcare Channels Offer More Personalised Services
Increased Product Segmentation According To Age and Gender
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Vitamins & Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
  Summary 1 Consumer Healthcare Switches 2007 -2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Cerebos Pacific Ltd
Strategic Direction
Key Facts
  Summary 3 Cerebos Pacific Ltd: Key Facts
  Summary 4 Cerebos Pacific Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 5 Cerebos Pacific Ltd: Competitive Position 2009
EU Yan Sang International Ltd
Strategic Direction
Key Facts
  Summary 6 Eu Yan Sang International Ltd: Key Facts
  Summary 7 Eu Yan Sang International Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 8 Eu Yan Sang (S) Pte Ltd: Competitive Position 2009
Haw Par Healthcare Ltd
Strategic Direction
Key Facts
  Summary 9 Haw Par Healthcare Ltd: Key Facts
  Summary 10 Haw Par Healthcare Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 11 Haw Par Healthcare Ltd: Competitive Position 2009
Integrated Contract Manufacturing Pte Ltd
Strategic Direction
Key Facts
  Summary 12 Integrated Contract Manufacturing Pte Ltd: Key Facts
Company Background
Production
Competitive Positioning
  Summary 13 Integrated Contract Manufacturing Pte Ltd: Competitive Position 2009
Vitahealth Asia Pacific (s) Pte Ltd
Strategic Direction
Key Facts
  Summary 14 VitaHealth Asia Pacific (S) Pte Ltd: Key Facts
Company Background
Production
Competitive Positioning
  Summary 15 VitaHealth Asia Pacific (S) Pte Ltd: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2005-2009
  Table 13 Sales of OTC Obesity: % Value Growth 2005-2009
  Table 14 OTC Obesity Company Shares by Value 2005-2009
  Table 15 OTC Obesity Brand Shares by Value 2006-2009
  Table 16 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 17 Forecast Sales of OTC Obesity: % Value Growth 2009-2014